Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib and Radiation in Local-stage MALT Lymphoma
NCT06583837Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in mucosa associated lymphoid tissue lymphoma, sponsored by Fudan University. Started Sep 2024; status: active, not recruiting.
02
Drugs
orelabrutinib
03
Conditions
mucosa associated lymphoid tissue lymphoma
Beyond the preview
Go deeper on NCT06583837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583837.